SEARCH

SEARCH BY CITATION

References

  • 1
    Goadsby PJ, Ramadan NM. Potential new drugs for acute and prophylactic treatment of migraines. In: Olesen J , Goadsby PJ , Ramadan NM , Tfelt-Hansen P , Welch KMA , eds. The Headaches, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:569-576.
  • 2
    Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (Depacon) aborts migraine rapidly: A preliminary report. Headache. 2000;40:720-723.
  • 3
    Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
  • 4
    Silberstein SD. Migraine and medication overuse. In: Schoenen J , Dodick DW , Sandor PS , eds. Comorbidity in Migraine. Sussex, UK: Wiley-Blackwell; 2011:96-111.
  • 5
    Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study. Cephalalgia. 2010;30:321-328.
  • 6
    Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population based study. Headache. 2008;48:1157-1168.
  • 7
    Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454.
  • 8
    Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc. 2007;82:61-68.
  • 9
    Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia. 2011;31:18-30.
  • 10
    Diamond S, Freitag FG, Diamond ML. Open-label trial of frovatriptan 2.5mg oral tablets in subjects with high frequency of migraine. Headache. 2008;48(Suppl 1):S50. Abstract#S27.
  • 11
    Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004;24(Suppl. 1):8-160.
  • 12
    Lipton RB, Cady RK, Farmer K. Bigal ME. Managing Migraine: A Healthcare Professional's Guide to Collaborative Migraine Care. Hamilton, ON: Baxter Publishing Inc.; 2008:26-27.
  • 13
    Silberstein SD, Olesen J, Bousser MG, et al; International Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460-465.
  • 14
    DeFelice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: A possible basis for medication overuse headache. Ann Neurol. 2010;67:325-337.
  • 15
    Göbel H, Stolze H, Heinze A Dworschak M. Easy therapeutic management of sumatriptan-induced daily headache. Neurology. 1996;47:297-298.
  • 16
    Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483-490.
  • 17
    Radat F, Creac'h C, Guegan-Massardier E, et al. Behavioral dependence in patients with medication overuse headache: A cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008;48:1026-1036.
  • 18
    Holland S, Silberstein SD, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346-1353.
  • 19
    Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: A prospective pilot study. Headache. 2005;45:1400-1406.
  • 20
    Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-1345.
  • 21
    Rapoport AM, Bigal ME, Volcy M, et al. Naratriptan in the preventive treatment of refractory chronic migraine: A review of 27 cases. Headache. 2003;43:482-489.
  • 22
    Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:335-340.
  • 23
    Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res. 2005;2:355-365.
  • 24
    Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76:711-718.
  • 25
    Diener HC, Limmroth V. Medication-overuse headache: A worldwide problem. Lancet Neurol. 2004;3:475-483.